Biosimilars Are Gaining Ground, but PBM Economics Still Shape Access

The growing adoption of biosimilars offers a potential solution to rising prescription drug costs, while pharmacy benefit manager (PBM) economics continue to influence which medications patients can access. Rebate structures, formulary decisions, and financial incentives post challenges that may limit the cost-saving potential of biosimilars.